BioScrip, Inc. (NASDAQ:BIOS) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 8.26%.
BioScrip, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased 66.67% to $0.04 in the quarter versus EPS of $0.12 in the year-earlier quarter.
Revenue: Decreased 62.61% to $180.7 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: BioScrip, Inc. reported adjusted EPS income of $0.04 per share. By that measure, the company beat the mean analyst estimate of $0.01. It beat the average revenue estimate of $173.87 million.
Quoting Management: “We are pleased to report solid fourth quarter performance. Our consolidated results reflect continued progress in the execution of our strategic goals and growth in our infusion business. Overall, 2012 was a year of positive progress and momentum for BioScrip. We accomplished a number of our key objectives towards repositioning the Company to focus on our infusion and home health businesses. In 2013, we will continue to build on our organic growth initiatives, which will be augmented with targeted acquisitions. The core drivers of organic growth will be delivering on our strong clinical programs, flexible go-to-market approach, and high-touch customer service model,” said Rick Smith, President and Chief Executive Officer of BioScrip.
Key Stats (on next page)…